Premium
Toll‐like receptor 4 is activated by platinum and contributes to cisplatin‐induced ototoxicity
Author(s) -
Babolmorad Ghazal,
Latif Asna,
Domingo Ivan K,
Pollock Niall M,
Delyea Cole,
Rieger Aja M,
Allison W Ted,
Bhavsar Amit P
Publication year - 2021
Publication title -
embo reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.584
H-Index - 184
eISSN - 1469-3178
pISSN - 1469-221X
DOI - 10.15252/embr.202051280
Subject(s) - ototoxicity , cisplatin , tlr4 , toll like receptor , in vivo , cancer research , lipopolysaccharide , pharmacology , chemistry , receptor , immunology , medicine , biology , innate immune system , biochemistry , chemotherapy , microbiology and biotechnology
Toll‐like receptor 4 (TLR4) recognizes bacterial lipopolysaccharide (LPS) and can also be activated by some Group 9/10 transition metals, which is believed to mediate immune hypersensitivity reactions. In this work, we test whether TLR4 can be activated by the Group 10 metal platinum and the platinum‐based chemotherapeutic cisplatin. Cisplatin is invaluable in childhood cancer treatment but its use is limited due to a permanent hearing loss (cisplatin‐induced ototoxicity, CIO) adverse effect. We demonstrate that platinum and cisplatin activate pathways downstream of TLR4 to a similar extent as the known TLR4 agonists LPS and nickel. We further show that TLR4 is required for cisplatin‐induced inflammatory, oxidative, and cell death responses in hair cells in vitro and for hair cell damage in vivo . Finally, we identify a TLR4 small molecule inhibitor able to curtail cisplatin toxicity in vitro . Thus, our findings indicate that TLR4 is a promising therapeutic target to mitigate CIO.